Accuray Incorporated

Accuray reports revenue across five regions: the Americas, EIMEA, Japan, China, and Asia Pacific, reflecting a globally distributed customer base. For the nine months ended March 31, 2025, EIMEA was the largest region by net revenue (105.3m), followed by China (93.9m), the Americas (58.4m), Japan (38.2m), and Asia Pacific (35.1m). The company sells directly in the U.S. and maintains international offices in Switzerland (Morges), Hong Kong, Shanghai, and Tokyo, with direct sales staff in much of Western Europe, Japan, India, and Canada. Distributor coverage extends across Europe, Russia, the Middle East, Africa, Asia Pacific, and Latin America, which increases exposure to local regulatory approvals, tender dynamics, and foreign currency movements.

Accuray’s revenue is exposed to long and variable sales and installation cycles for CyberKnife and TomoTherapy systems, which can create quarter-to-quarter volatility and make backlog conversion sensitive to customer site readiness. Customer concentration is a disclosed risk, as one customer has represented 10% or more of total net revenue in multiple years, so deferrals or cancellations can materially affect results. The company operates in a heavily regulated environment where upgrades, modifications, and new indications may require FDA 510(k) clearances or other international approvals, and failure to obtain/maintain approvals can block sales in specific countries. Additional risks include cybersecurity threats affecting sensitive data and operations, intellectual property litigation or protection challenges, and compliance risks tied to financial relationships with physicians and customers (e.g., grants, prior loans, volume-related arrangements).